Biogen Inc BIIB

$254.46 +5.53 (2.22%)

Valuation

Market cap
36,796,832,000
Revenue TTM
$9,890,600,000
Net income TTM
$1,292,900,000
P/E (trailing)
21.14
P/E (forward)
19.97
Profit margin
13.07%
Debt to equity
0.39

Trading

Volume
1,347,900
Avg volume
1,138,046
Day's range
$246.49 – $255.35
Shares out
147,820,000
Stochastic %K
73%
Beta
0.10
Analysts
Moderate Buy
Price target
$265.19

Price

Company profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etan...

Show more

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
617 679 2000
Website
https://www.biogen.com
Address
225 Binney Street, Cambridge, United States

Latest news

Stocktwits

Axos300 Nov 4, 10:44 PM
$BIIB this stock is goofy as hell. I think people are day trading it. Looking for the exits.
0 replies
Quantumup Nov 4, 7:33 PM
Bernstein Societe Generale reiterated $NBIX Outperform-$218 and said--As we have stated before, here at The Drug Developers we like market creation stories in patient populations with clinically meaningful unmet need. [ $BIIB [VRTX HLUBF HLBBF OMass Therap, [TEVA BHC QURE Mitsubishi [RYTM RLMD HRMY]]]] Here's what else Bernstein Societe Generale had to say: https://x.com/Quantumup1/status/2118064008347730418?a=L20X9kF62FsjobtV6sA&s=20
0 replies
OldManLogan Nov 3, 4:48 PM
$LRMR $LXEO $BIIB Glad for FA patients to have more options, but uptake for gene therapy for rare disease has been notoriously poor... for that reason and the fact that LRMR is as much as a couple of years ahead in the process, LRMR is my clear choice... I fully expect that LRMR will be bought out before LXEO even hits the market.
2 replies
SparkyReturns Nov 3, 3:58 PM
$AMGN So now, sitting at a mere 10M Market Cap, Seastar (ICU) will generate more revenue than that in 2027 with today's removal of the registry requirement. 7 BDDs, with the most recent for Sepsis as a standalone indication. TAM easily in the billions once adult use approved in early/mid-2027. Pediatric already approved under HDE. Incredibly underpriced. Related biotechs that supply tubing, equipment, and medicines for Sepsis, AKI, cancer, and heart disease could also be affected. https://investors.seastarmedical.com/news-releases/news-release-details/fda-confirms-seastar-medical-has-fulfilled-post-approval-study $GILD $VRTX $BIIB $BMRN
0 replies
FelixH86 Nov 3, 11:40 AM 0 replies
11thestate Nov 2, 1:29 PM
Everything you need to know about the $18.9M Biogen ($BIIB) Settlement Payout Q: What happened? A: Biogen allegedly misled investors about the commercial launch of Aduhelm, its Alzheimer’s treatment, by overstating payer support and suggesting that Medicare coverage was automatically available after FDA approval. Later disclosures revealed uncertainty around reimbursement and patient access, raising concerns about the drug’s commercial prospects. Q: Am I actually eligible? A: If you bought $BIIB shares in 2021, you’re likely eligible. You don’t need to still hold the stock to claim; past losses count Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Q: I missed the deadline. Is it too late? A: No, you may still be able to file a late claim, but acceptance depends on final approval by the court. Check if you're eligible and file a claim: https://11th.com/cases/biib-investor-settlement
0 replies
GoforProMIS Nov 2, 12:21 PM
$PMN $PMN When $LLY and $BIIB works with IgG1 and ProMIS hat the same isotype target but 0 ARIA why would someone compare $ABOS versus Promis ? Soon after unblinding it will show ProMIS is the best AD in class!
0 replies
NVDAMillionaire Nov 2, 7:23 AM
$BIIB Excellent article that nails exactly where BIIB stands right now. So if you want to update your BIIB knowledge or get acquainted with BIIB, this is a must read. https://everyticker.com/quote/BIIB/analysis/biogen-s-immunology-inflection-why-the-apellis-acquisition-marks-the-end-of-the-ms-era-nasdaq-biib
0 replies